Haoyang Xiong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haoyang Xiong has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Di Wang
Jilin Provincial Key Laboratory of Animal Embryo Engineering, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Jilin University, Changchun 130062, China
1 shared publication - Ding Zhao
Jilin Provincial Key Laboratory of Animal Embryo Engineering, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Jilin University, Changchun 130062, China
1 shared publication - Feiyu Zhao
Jilin Provincial Key Laboratory of Animal Embryo Engineering, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Jilin University, Changchun 130062, China
1 shared publication - Hongmei Liu
Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Functional Nucleic Acids-Based Biopharmaceutical Research, Guizhou Biomanufacturing Laboratory, Guizhou Medical University, Guiyang 550031, China
1 shared publication - Liangxue Lai
Institute of Development and Regeneration, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, China
1 shared publication - Mingyang Hu
Jilin Provincial Key Laboratory of Animal Embryo Engineering, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Jilin University, Changchun 130062, China
1 shared publication
Latest Publications
- Open Access
- 15 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (11) , eadk8052
Precise large-fragment deletions in mammalian cells and mice generated by dCas9-controlled CRISPR/Cas3
Currently, the Cas9 and Cas12a systems are widely used for genome editing, but their ability to precisely generate large chromosome fragment deletions is limited. Type I-E CRISPR mediates broad and unidirectional DNA degradation, but controlling the size of Cas3-mediated DNA deletions has proven elusive thus far. Here, we demonstrate that the endonuclease deactivation of Cas9 (dCas9) can precisely control Cas3-mediated large-fragment deletions in mammalian cells. In addition, we report the elimination of the Y chromosome and precise retention of the Sry gene in mice using CRISPR/Cas3 and dCas9-controlled CRISPR/Cas3, respectively. In conclusion, dCas9-controlled CRISPR/Cas3-mediated precise large-fragment deletion provides an approach for establishing animal models by chromosome elimination. This method also holds promise as a potential therapeutic strategy for treating fragment mutations or human aneuploidy diseases that involve additional chromosomes.
- 15 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (11) , eadk8052
Open AccessPrecise large-fragment deletions in mammalian cells and mice generated by dCas9-controlled CRISPR/Cas3
Currently, the Cas9 and Cas12a systems are widely used for genome editing, but their ability to precisely generate large chromosome fragment deletions is limited. Type I-E CRISPR mediates broad and unidirectional DNA degradation, but controlling the size of Cas3-mediated DNA deletions has proven elusive thus far. Here, we demonstrate that the endonuclease deactivation of Cas9 (dCas9) can precisely control Cas3-mediated large-fragment deletions in mammalian cells. In addition, we report the elimination of the Y chromosome and precise retention of the Sry gene in mice using CRISPR/Cas3 and dCas9-controlled CRISPR/Cas3, respectively. In conclusion, dCas9-controlled CRISPR/Cas3-mediated precise large-fragment deletion provides an approach for establishing animal models by chromosome elimination. This method also holds promise as a potential therapeutic strategy for treating fragment mutations or human aneuploidy diseases that involve additional chromosomes.